Brief: Dermapharm Expects 2021 Consolidated EBITDA To Increase By 45%-50%

Dermapharm Holding SE

13/04/2021 06:35

April 13 (Reuters) - DERMAPHARM HOLDING SE  DMPG.DE :
    * DERMAPHARM FORECASTS EXCEPTIONALLY STRONG GROWTH FOR 2021
AND
CONFIRMS PRELIMINARY FIGURES
    * DIVIDEND 0.88 EURPER SHARE
    * FY REVENUE ROSE 13.3 PERCENT TO 793.8 MILLION EUR
    * CONSOLIDATED EBITDA TO INCREASE BY 45 % - 50 % IN 2021
    * DIVIDEND PROPOSAL OF EUR 0.88 PER SHARE FOR 2020
    * CONSOLIDATED REVENUE TO GROW BY 24 % - 26 % IN 2021
    * VACCINE PRODUCTION TO COMMENCE IN MAY 2021 AT
ALLERGOPHARMA'S
SITE IN REINBEK
    * CONFIRMS PRELIMINARY FIGURES
    * CONFIRMS ITS PRELIMINARY CONSOLIDATED FIGURES FOR
FINANCIAL YEAR
2020

Source text for Eikon:  ID:nEQ5Vht0fa 
Further company coverage:  DMPG.DE 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 778 51 10;))